<DOC>
	<DOCNO>NCT01811576</DOCNO>
	<brief_summary>The primary objective study evaluate clinical effect TV-1106 .</brief_summary>
	<brief_title>Safety , Tolerability Efficacy Weekly TV-1106 Adults With Growth Hormone Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Patient agree provide write informed consent comply study protocol reading inform consent discuss study investigator . Males females 23 65 year age must confirm diagnosis adult GHD , either adult onset ( AO ) GHD due hypothalamicpituitary disease childhood onset ( CO ) GHD either idiopathic due hypothalamicpituitary disease due genetic cause . Diagnosis GH deficiency must confirm document ( medical record ) diagnostic testing . Patients treat stable dose daily rhGH least 3 month prior screen . Other criterion apply . Patients history clinical evidence active chronic disease could confound result study put subject undue risk determine investigator . Patients know active malignancy Patients history malignancy intracranial tumor cause GHD ( exclude surgically cure basal cell squamous cell cancer skin document 6 month remission ) Patients evidence pituitary adenoma intracranial tumor within 12 month enrollment , day 0 ( baseline , Visit 3 ) Patients without magnetic resonance imaging ( MRI ) computerize tomography ( CT ) data document tumor stability within 12 month prior enrollment , day 0 ( baseline , Visit 3 ) Presence PraderWilli syndrome , Turner 's syndrome , untreated adrenal insufficiency , active acromegaly past 5 year , active Cushing 's syndrome past 1 year . Other criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>23 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Growth hormone deficiency</keyword>
	<keyword>Insulin-like growth factor I ( IGF-I )</keyword>
	<keyword>TV-1106</keyword>
</DOC>